Almonty Industries Inc. (ALM)
NASDAQ: ALM · Real-Time Price · USD
18.04
-0.85 (-4.50%)
At close: Aug 28, 2026, 4:00 PM EDT
18.06
+0.02 (0.11%)
After-hours: Aug 28, 2026, 7:54 PM EDT
Almonty Industries Revenue
Almonty Industries had revenue of 42.99M CAD in the quarter ending June 30, 2026, with 497.73% growth. This brings the company's revenue in the last twelve months to 85.80M, up 204.55% year-over-year. In the year 2025, Almonty Industries had annual revenue of 32.51M with 12.75% growth.
Revenue (ttm)
85.80M CAD
Revenue Growth
+204.55%
P/S Ratio
86.13
Revenue / Employee
251,622 CAD
Employees
341
Market Cap
5.20B USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 32.51M | 3.68M | 12.75% |
| Dec 31, 2024 | 28.84M | 6.33M | 28.10% |
| Dec 31, 2023 | 22.51M | -2.29M | -9.22% |
| Dec 31, 2022 | 24.80M | 3.95M | 18.94% |
| Dec 31, 2021 | 20.85M | -4.25M | -16.93% |
| Dec 31, 2020 | 25.10M | -40.08M | -61.49% |
| Sep 30, 2018 | 65.17M | 26.15M | 67.03% |
| Sep 30, 2017 | 39.02M | 1.71M | 4.58% |
| Sep 30, 2016 | 37.31M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nexa Resources | 3.46B |
| Materion | 2.10B |
| MP Materials | 416.25M |
| Elevra Lithium | 202.07M |
| Americas Gold and Silver | 181.59M |
| Sigma Lithium | 142.49M |
| USA Rare Earth | 13.16M |
ALM News
- 13 days ago - Almonty announces new share repurchase program of up to $300M - TheFly
- 13 days ago - Almonty Announces New Share Repurchase Program of Up to US$300,000,000 - Business Wire
- 16 days ago - Diamond Equity Research Releases Update Note on Almonty Industries, Inc. (Nasdaq: ALM; Frankfurt: ALI1) - GlobeNewsWire
- 19 days ago - Almonty Industries Reports Second Quarter 2026 Financial Results - Business Wire
- 5 weeks ago - Almonty to voluntarily delist from ASX - TheFly
- 5 weeks ago - Almonty to Voluntarily Delist From ASX - Business Wire
- 5 weeks ago - Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older - Business Wire
- 6 weeks ago - Almonty to voluntarily delist from TSX - TheFly